At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Not Yet Opened 10-27 16:00:00 EDT
447.95
+3.32
+0.75%
盘后450.26
+2.31+0.52%
19:45 EDT
High448.55Low439.28Vol1.73M
Open441.80D1 Closing444.63Amplitude2.08%
Mkt Cap241.21BTradable Cap240.55BTotal Shares538.48M
T/O774.66MT/O Rate0.32%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Amgen revenue expected to increase by 12.31%, institutional views lean positive
Earnings Agent  ·  10-27 12:34
Earning Preview: Amgen revenue expected to increase by 12.31%, institutional views lean positive
RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)
TIPRANKS  ·  09:56
RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)
Amgen Announces 2026 Fourth Quarter Dividend
THOMSON REUTERS  ·  06:28
Amgen Announces 2026 Fourth Quarter Dividend
Amgen - Declares Q4 2026 Dividend of $2.52 Per Share
THOMSON REUTERS  ·  06:28
Amgen - Declares Q4 2026 Dividend of $2.52 Per Share
Press Release: AMGEN Announces 2026 Fourth Quarter Dividend
Dow Jones  ·  06:28
Press Release: AMGEN Announces 2026 Fourth Quarter Dividend
Beta Bionics Q3 Adjusted Ebitda Misses Estimates
Reuters  ·  04:11
Beta Bionics Q3 Adjusted Ebitda Misses Estimates
Amgen Study Finds Bone Marrow Immune Cells Can Enter Aging Brain
Reuters  ·  03:43
Amgen Study Finds Bone Marrow Immune Cells Can Enter Aging Brain
FDA says Amgen’s video ads for Vectibix ‘false or misleading’
TIPRANKS  ·  03:20
FDA says Amgen’s video ads for Vectibix ‘false or misleading’
FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure of Communications
Reuters  ·  02:29
FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure of Communications
FDA Warns Amgen over Cancer Drug Promotional Video
Reuters  ·  02:25
FDA Warns Amgen over Cancer Drug Promotional Video
FDA: Amgen Ordered to Cease Misleading Vectibix Promotional Communications; Faces Seizure and Injunction if Violations not Corrected
THOMSON REUTERS  ·  01:34
FDA: Amgen Ordered to Cease Misleading Vectibix Promotional Communications; Faces Seizure and Injunction if Violations not Corrected
FDA: Amgen Vectibix Promotional Video Found False or Misleading - Website
THOMSON REUTERS  ·  01:34
FDA: Amgen Vectibix Promotional Video Found False or Misleading - Website
FDA: Amgen Vectibix Video Omits Material Risk Information Including Dermatologic Toxicity, Infusion Reactions, Pulmonary Fibrosis
THOMSON REUTERS  ·  01:34
FDA: Amgen Vectibix Video Omits Material Risk Information Including Dermatologic Toxicity, Infusion Reactions, Pulmonary Fibrosis
Kiniksa Pharmaceuticals Q3 Arcalyst Revenue Jumps 58%; Raises Guidance
Reuters  ·  10-27 19:41
Kiniksa Pharmaceuticals Q3 Arcalyst Revenue Jumps 58%; Raises Guidance
Nautilus Biotechnology Q3 Revenue Beats
Reuters  ·  10-27 18:12
Nautilus Biotechnology Q3 Revenue Beats
Amgen names David Gibbs to board of directors
TIPRANKS  ·  10-27 06:00
Amgen names David Gibbs to board of directors
Amgen Appoints David W. Gibbs to Board of Directors
THOMSON REUTERS  ·  10-27 05:52
Amgen Appoints David W. Gibbs to Board of Directors
Press Release: AMGEN Appoints DAVID W. GIBBS to BOARD of Directors
Dow Jones  ·  10-27 05:52
Press Release: AMGEN Appoints DAVID W. GIBBS to BOARD of Directors
European Stocks Close Higher in Monday Trading as Oil Prices Ease, Bond Yields Stabilize
MT Newswires Live  ·  10-27 00:07
European Stocks Close Higher in Monday Trading as Oil Prices Ease, Bond Yields Stabilize
Moderna's Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
Dow Jones  ·  10-26 22:52
Moderna's Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--